E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV). |
|
E.1.1.1 | Medical condition in easily understood language |
Irritation and inflammation of the stomach and intestines (diarrhoea) or stomach flu caused by Human Rota virus. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10021881 |
E.1.2 | Term | Infections and infestations |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that the immunogenicity to the antigens contained in DPT-IPV vaccine is not impaired by the co-administration with GSK Biologicals' liquid HRV vaccine. |
|
E.2.2 | Secondary objectives of the trial |
• To assess the immunogenicity of the liquid HRV vaccine in terms of serum anti-RV IgA antibody seropositivity and GMCs in a sub-cohort of subjects, 1 month after the sec-ond dose of the liquid HRV vaccine.
• To assess the immunogenicity to all the antigens contained in the DPT-IPV vaccine in terms of GMCs/ geometric mean antibody titres (GMTs), 1 month after the third dose of the DPT-IPV vaccine.
• To assess reactogenicity and safety after each dose of liquid HRV vaccine and first dose of DPT-IPV vaccine in terms of solicited symptoms during the 8-day follow-up period and unsolicited symptoms during the 31-day follow-up period.
• To assess safety in terms of serious adverse events (SAEs) from the first dose of study vaccine up to study end.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Subjects’ parent(s)/ Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator can and will comply with the requirements of the protocol.
• A male or female between, and including, 6 and 12 weeks of age at the time of the first dose of HRV vaccination.
• Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• Born full-term as per the delivery records. |
|
E.4 | Principal exclusion criteria |
• Child in care.
• Use of any investigational or non-registered product other than the study vaccines within 30 days before the first dose of study vaccine, or planned use during the study period.
• Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone (>= 0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed.
• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
• Administration of long-acting immune-modifying drugs at any time during the study period.
• Planned administration/administration of a vaccine not fore-seen by the study protocol within the period starting 30 days before the first dose of HRV vaccine administration and ending at Visit 7, with the exception of other routinely administered vaccines like PCV, Hib, BCG, hepatitis B, meningococcal vaccine and inactivated influenza vaccines, which are allowed at any time during the study, if administered at sites different from the sites used to administer the DPT-IPV vaccine.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
• Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS).
• History of IS.
• Family history of congenital or hereditary immunodeficiency.
• Any confirmed or suspected immunosuppressive or immu-nodeficient condition, based on medical history and physical examination.
• Major congenital defects or serious chronic illness.
• Previous vaccination against rotavirus, diphtheria, tetanus, pertussis and/ or poliovirus.
• Previous confirmed occurrence of RV GE, diphtheria, tetanus, pertussis, and/ or polio disease.
• GE within 7 days preceding the HRV vaccine administration.
• History of any reaction or hypersensitivity likely to be exac-erbated by any component of the HRV or DPT-IPV vaccines.
• Hypersensitivity to latex.
• History of any neurological disorders or seizures.
• History of SCID.
• Acute disease and/or fever at the time of enrollment.
- Fever is defined as temperature ≥ 37.5°C /99.5°F on oral, axillary or tympanic setting, or ≥ 38.0°C /100.4°F on rectal setting.
- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity with respect to components of the DPT-IPV vaccine.
• anti-diphtheria antibody concentrations ≥ 0.1 IU/mL,
• anti-tetanus antibody concentrations ≥ 0.1 IU/mL,
• anti-PT and anti-FHA antibody concentrations ≥ 10 EU/mL,
• anti-poliovirus serotypes 1, 2 and 3 antibody titre ≥ 8 ED50
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
One month after administration of the third dose of the DPT-IPV vaccine (Visit 7). |
|
E.5.2 | Secondary end point(s) |
• Serum anti-RV IgA antibody concentration greater and equal to 20 U/mL and seropositivity in a sub-cohort of subjects.
• Serum GMCs/GMTs for anti-diphtheria, anti-tetanus, anti-poliovirus serotypes 1, 2 and 3, anti-PT and anti-FHA antibodies.
• Occurrence of solicited general symptoms.
• Occurrence of solicited local and general symptoms.
• Occurrence of unsolicited AEs.
• Occurrence of SAEs. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• One month after the second dose of the liquid HRV vaccine.
• One month after the third dose of the DPT-IPV vaccine.
• During the 8-day (Days 0-7) follow-up period after each dose of liquid HRV vaccine.
• During the 8-day (Days 0-7) follow-up period after the first dose of DPT-IPV vaccine.
• During the 31-day (Days 0-30) follow-up period after each dose of the liquid HRV vaccine and the first dose of DPT-IPV vaccine.
• From the first dose of the study vaccine up to study end (Visit 7). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last testing results released of samples collected at Visit 7. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |